Topic Listing for Pharmos

Absence Registration Obligations Absence Undisclosed Liabilities
Accounting Asset Retirement Obligations Accounting Conditional Asset Retirement Obligations Interpretation Fasb Statement
Accounting Uncertainty Income Taxes Fin Accounting Uncertainty Income Taxes Ldquofin 48rdquo
Accuracy Representations Warranties Parent Sub Accuracy Representations Warranties Target
Accurate Books Records Acquisition Events Other Adjustment Shares
Acquisition Vela Pharmaceuticals Inc Additional Compensation
Additional Information Additional Information Acquisition Find
Additional Information Merger Find Adjustments
Adjustments Awards Adjustments Case Certain Transactions
Administration Administration Escrow Account
Advice Change Against
Aggregated Option Exercises 2005 Values Agreement Plan Merger
Agreements Vote Favor Merger Alan Rubino
Amendment Amendment 193
Amendment 2000 Stock Option Plan Amendment 611
Amendment 715 Amendment 810
Amendment Agreement Plan Merger Amendment Agreement Plan Merger Among Pharmos Corporation Vela
Amendment Form Escrow Agreement Amendment Form Registration Rights Agreement
Amendment Form Standstill Agreement Amendment Modification Waiver
Amendment Registration Rights Agreement Amendment Repeal
Amendments Amendments Articles Incorporation Bylaws Change
Annual Bonus Annual Meeting Vote
Annual Report Form 10-k Annual Report Pursuant Securities Exchange Act 1934
Anthony Evnin Phd Antidilution
Appendix Applicable Law Jurisdiction
Application Limitation Grants Awards Appointment Escrow Agent
Appointment New Ceo Appointment Representatives
Approval Approval Parent Stockholders
Approval Parent Stockholders Delivery Certificate Merger Approval Target Stockholders Delivery Certificate Merger
Assets Assignment Benefits Agreement
Assumes Phase Ibs Startup Activities Patient Enrollment Beginning Audit Committee Report
Audit Fees Audit-related Fees
Authority Committee Availability Sec Filings
Availability Shares Not Delivered Awards Adjustments Limits Award
Award Agreement Award Restrictions
Background Balance Page Been Left Blank Intentionally
Base Salary Basis Consolidation
Basis Presentation Bausch Lomb
Beneficial Ownership Reporting Compliance Beneficial Ownership8221
Beneficiary Benzo
Bicyclic Cb2-selective Cannabinoids Board Changes
Board Committees Board Directors Meetings Committees
Board Directors Unanimously Recommends Vote Each Director Nominees Board Management Changes
Bonus Stock Awards Lieu Obligations Bonuses 2006 Compensation Determinations 2007
Bonuses 2007 Compensation Determinations 2008 Books Records
Brokers Burrill
Business Objectives Cancelled Bridge Notes
Cannabinor Cannabinor Cb2-selective Cannabinoids
Capital Expenditures Capitalization
Capitalized Merger Costs Capsaicin-induced Pain
Carry Regular Course Cash
Cash Compensation Cash Consideration
Cash Equivalents Cause
Cause Defined Cb2-selective Cannabinoids
Certain Anti-takeover Provisions Also Subject Nevada Make Difficult Certain Definitions Used Herein Following Terms Not Otherwise
Certain Obligations Indemnify Officers Directors Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Transactions
Certificate Chief Executive Officer Certificate Chief Financial Officer
Certificates Stock Change Control
Change Control Defined Change Director Compensation 2008
Change Lead Director Fee 2007 Change Vote After Mailed Signed Proxy Card
Changes Internal Control Over Financial Reporting Changes Plan Awards
Charles Newhall Chief Executive Officer Transition
Class Action Lawsuits Class Action Suits
Clinical Trials Depend Party Investigators Outside Control Closing Effective Date Merger
Code Code 409a
Code Ethics Colin Neill
Collaborative Agreements Collaborative Relationships
Commencement Employment Term Commitment Contingencies
Commitments Contingencies Committee
Committee Certification Common Stock
Common Stock Par Value Common Stock Transactions
Communications Board Directors Comparable Mergers Acquisitions Transactions Method
Comparable Public Companies Method Comparable Venture Capital Funding Transactions Method
Comparison 2006 2005 Compensation Committee Interlocks Insider Participation
Compensation Directors Compensation Discussion Analysis
Compensation Stock Option Committee Report Competition
Completion Acquisition Disposition Assets Compliance Laws
Compliance Laws Rules Regulations Compliance Legal Other Requirements
Compliance Other Instruments Laws Etc Compliance Parent Sub
Compliance Target Compounds Clinical Development
Concentration Credit Risk Conditions Israel
Conditions Israel Continue Volatile Conditions Parties Obligations
Conditions Precedent Parents Subs Obligations Conditions Precedent Targets Obligations
Conduct Parent Group Business Prior Effective Date Conduct Target Business Prior Effective Date
Confidential Information Publicity Confidentiality
Conflicts Interest Consent Independent Registered Public Accounting Firm
Consents Consents Parties
Consolidated Financial Statements Consultant
Consulting Contracts Employment Agreements Contacts
Continuous Service Contracts
Contracts Commitments Controls Procedures
Conversion Convertible Debenture Due 2012
Convertible Debentures Cooperation Preparation Required Securities Laws Documents
Corporate History Corporate Opportunities
Corporate Power Binding Effect Corporation
Corporation Automobile Corporation Information
Corporation Information Defined Counterparts
Covenants Parties Covered Employee8221
Covered Employees Critical Accounting Policies
Cum Laude Current Future Liquidity Position
Current Market Current Working Capital Position
David Bouchey Dcf Method
Default Defendant Class Action Lawsuits Determined Adversely Material Adverse
Defendant Class Action Lawsuits Shareholder Derivative Determined Adversely Deferred Stock
Deferred Stock Award Defined Terms
Definition 8220change Control8221 Definitions
Delaware Corporation Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Description 2000 Plan
Description Transaction Basis Presentation Details Transaction
Dextofisopam Dextofisopam Treat Ibs
Director Director Nomination Process
Director Resignations 2006 Director Retirements New Appointment 2008
Directors Directors Compensation
Disability Disability Defined
Disability Insurance Disclosure Statements
Distribution Parent Stock Dividend Equivalent
Dividend Equivalents Dividend Restrictions
Dividend Yield Dividends
Dividends Etc Dividends Issuances Repurchases Etc
Dividends Splits Drug Discovery Approach
Drug Enforcement Administration Duration Amendments
Early Stage Development Effect 8220change Control8221
Effective Date Effects New Accounting Standards
Electronic Delivery Proxy Statement Annual Report Saves Money Electronic Voting Saves Mone
Electronic Voting Saves Money Eligibility
Eligibility Form S-3 Eligibility Per-person Award Limitations
Eligible Person Elkan Gamzu
Employee Employee Benefit Plans
Employee Stock Purchase Plan Employees Directors Warrants Plan
Employment Employment Agreement
Employment Agreements Employment Consulting Contracts Directors Compensation
Employment Contracts Entire Agreement
Entitled Vote Proposals Meeting Entry Material Definitive Agreement
Eport Independent Registered Public Accounting Firm Equity Based Compensation
Equity Compensation Equity Compensation Plan Information
Escrow Agent Compensation Escrow Agreement
Escrow Fund Establishment Purpose
Estimates Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Exchange Act
Execution Execution Delivery Registration Rights Agreement Escrow
Executive Officers Compensation Paid 2006 Executive Officersrsquo Compensation Paid 2006
Executive Officersrsquo Compensation Paid 2007 Executive Sessions Independent Directors
Executive Stock Trading Program Executive Summary
Executive Summary 2007 Strategy Operating Plan Executive Summary 2008 Strategy Operating Plan
Exemptions Liability Exercise Conversion Stock Options Warrants Other Rights
Exercise Price Exhibits
Expansion Parent Board Directors Expected Term
Expected Volatility Expenses
Explanatory Face Extensive Governmental Regulation Failure Adequately Comply Prevent
Face Large Competitors Limited Financial Research Resources Limit Fair Dealing
Fair Market Value Fair Value Financial Instruments
Fairness Considerations Analysis Fda Comparable Authorities Other Countries
Filings Financial Statements
Financial Statements Exhibits Financial Statements Supplementary Data
Financing Activities Fixed Assets
Foreign Exchange Forfeiture
Form 10-k Form 10-q
Form Timing Payment Awards Deferrals Forms General Releases
Full Access Full Disclosure
Further Assurance Further Obligations
Gad Riesenfeld Phd General
General Executive Compensation Policy Gifts Gratuities
Good Reason Good Reason Defined
Governing Law Government Consents Etc
Governmental Consent Non-contravention Etc Grant Restrictions
Haim Aviv Phd Harris Nesbitt Analyst
Hazardous Materials Research Headings
Hereby Deleted Replaced Following History Operating Losses Expect Sustain Future
Hsr Filing Human Resources
Hypoactive Sexual Desire Disorder Immediate Release
Impairment Long Lived Assets Impairment Long-lived Assets
Important Important Message Board Directors
Incentive Stock Option Incentive Stock Options
Income Tax Benefit Income Taxes
Incorporation Incorporation Authority
Indebtedness Indemnification
Indemnification Contribution Indemnified Fund
Indemnifying Stockholders Independence Directors
Independent Index
Index Consolidated Financial Statements Insider Trading Securities Law Compliance
Instrument Accession Insurance
Internal Control Over Financial Reporting Internal Controls
Introduction Investing Activities
Investments Investors Security Holders Pharmos Urged Read Materials They
Irritable Bowel Syndrome Irritable Bowel Syndrome Disease Description Diagnosis
Ischemic Colitus Concerns Whole Category Present Safety Regulatory Iselin
Iselin 08830 Iselin 2005
Iselin 2006 Iselin 2007
Iselin 2008 Iselin New Jersey 08830
Iselin Rehovot Israel 2005 Iselin Rehovot Israel 2006
Iselin Rehovot Israel 2007 Israeli Tax Ordinance
James Meer Jim Meer
Joinder Labor Relations
Lack Manufacturing Capability Lawful Issuance
Ldquo Lead Director
Leases Legal Proceedings
Liabilities Shareholders Equity Liabilities Target
Licenses Limitation Liability
Limitation Overall Number Shares Available Delivery Plan Limitation Rights Conferred Plan
Limits Transferability Beneficiaries Liquidation
Liquidation Value Liquidity Business Risks
Liquidity Capital Resources List Indemnifying Stockholders
Listing Market8221 Litigation Etc
Loans Long Lived Assets Net
Long-lived Assets Loss Operations
Loteprednol Etabonate Lotronex Gsk
Low Management Changes
Management Urges Shareholders Support Vela Acquisition Managements Annual Report Internal Control Over Financial Reporting
Mandatory Redemption Manner Exercise Committee Authority
Market Potential United States Rest World Market Registrants Common Equity Related Stockholder Matters Issuer
Market Topical Nsaids Material Adverse Change
Material Modification Rights Security Holders Meeting
Merger Agreement Merger Occur
Merger Result Change Control Method Asserting Claims Payment Offset
Milfam Milfam Llc
Minute Books Miscellaneous
Miscellaneous Provisions Nanoemulsion Drug Delivery System
Nasdaq Listing Need Find Collaborative Partners
Net Income Loss Net Income Loss Per Common Share
Net Income Loss Per Share Net Loss
Net Loss Income Net Loss Per Common Share
Net Loss Per Share Net Operating Loss Shareholder Notice
Neuropathic Pain New Accounting Pronouncements
New Enterprise Associates Limited Partnership Non Renewal Corporation Expiration Initial Term Additional
Non-us Laws Nonexclusivity Plan
Not Able Obtain Financing Future Notice Annual Meeting Stockholders
Notice Hereby Given Notice Termination
Notice Termination Generally Notices
Now Therefore Number 0-11550
Obligations Stockholders Office
Office Chief Scientist Officer Transitions
Officers Officers Certificates
Operating Activities Operator
Opinion Targets Counsel Opinions Parents Subs Counsel
Opposition Vela Transaction Dissident Shareholders Option
Option Grants 2005 Optionee
Options Order Board Directors
Organization Standing Subsidiary Other
Other Adjustments Other Benefits
Other Compounds Other Events
Other Fees Other Income Expense
Other Income Expense Net Other Information
Other Matters Other Proceeds
Other Stock-based Awards Other Terms
Other Transactions Outside Closing Date
Overview Overview Proposed Acquisition Transaction
Ownership Parent Stock Page
Parent Parent Act Behalf Affiliates
Parent Stockholders Meeting Parent Sub Certificates
Parent Sub Disclosure Schedules Participant
Parties Merger Patents
Patents Proprietary Rights Pay Vela
Payment Cash Consideration Payment Shares
Payment Terms Payment Timing Consideration
Payments Event Forfeitures Fractional Shares Performance Award
Performance Awards Performance Criteria
Performance Graph Performance Period
Performance Period Timing Establishing Goals Performance Share
Performance Unit Person
Pharmos Pharmos Advanced Position Several Novel Proprietary Scaffolds
Pharmos Agrees Acquire Vela Pharmaceuticals Inc Pharmos Commences Patient Dosing Phase Cannabinor Nociceptive Pain
Pharmos Commences Phase Irritable Bowel Syndrome Study Pharmos Completes Phase Study Topical Diclofenac Nanoemulsion Cream
Pharmos Corporate Development Pharmos Corporation
Pharmos Corporation Announces President Coo Alan Rubino Leave Pharmos Corporation Clinical Development Scientific Committee Charter
Pharmos Corporation Code Ethics Business Conduct Effective-february 2004 Pharmos Corporation Consolidated Statements Changes Shareholders Equity Notes
Pharmos Corporation Exact Name Registrant Specified Charter Pharmos Corporation Index Consolidated Financial Statements
Pharmos Corporation Investor Presentation Dated 2006 Pharmos Corporation Reports 2005 Results
Pharmos Corporation Wood Avenue South Suite 311 Iselin Pharmos Initiate Clinical Program Tissue-directed Treatment Inflammation Pain
Pharmos Present Rodman Renshaw Techvest Annual Global Healthcare Pharmos Receives Grant
Pharmos Receives Grant Israel Government Pharmos Stock Price History
Pharmos Svp Cfo Pharmos Vela Pro Forma Condensed Combined Financial Statements
Phase Iia Trial Dexanabinol Prevent Cognitive Impairment Following Phase Trial Dexanabinol Treatment Severe Tbi
Piggyback Registration Placement
Plan Plan 2000
Plan Effective Date Shareholder Approval Termination Platform Technologies
Policy Audit Committee Pre-approval Non-audit Services Independent Auditor Policy Regarding Director Attendance Annual Stockholdersrsquo Meetings
Political Contributions Position Duties
Post-closing Covenants Potential Conflicts Interest
Potential Develop Sexual Dysfunction Females Potential Pharmaceutical Market Dextofisopam
Potential Pharmaceutical Markets Pharmos Bicyclic Cb2-selective Cannabinoids Potential Pharmaceutical Markets Pharmos Cb2-selective Cannabinoids
Potential Pharmaceutical Markets Pharmosrsquo Cb2-selective Cannabinoids Preferred Stock Dividends
Preliminary Statement Prescriptions 2005
Preservation Organization Prevalence Ibs
Price Common Stock Experience Volatility Principal Accountant Fees Services
Principal Accounting Fees Services Private Investments Co-investments Outside Business Activities Employees Officers
Private Placement Private Placement Convertible Debentures
Private Placement Convertible Debt Proceedings Documents Satisfactory
Product Candidates Not Successfully Complete Clinical Trials Required Product Pipeline Milestones
Projected 2006 Properties
Property Equipment Proposing Acquire Vela
Protect Investment Staying Informed Protection Proper Property
Proven Effective Proxy
Proxy Statement Other Relevant Materials They Become Available Public Funding Grants
Public Statements Releases Purchase Price
Purchaser Purpose
Pursuant Nrs 78385 78390 After Issuance Stock Qualification
Quantitative Qualitative Disclosures Market Risk Ratification Selection Independent Registered Public Accounting Firm
Ray Mckee Rbc Capital Markets Analyst
Rbc Capital Markets Corporation Rdquo
Recent Accounting Pronouncements Recent Developments
Reclassifications References Parent Stock Sections
Registration Rights Agreement Registration Rights Agreement Signature Page Pharmos
Registration Rights Agreement Signature Page Representatives Regulation Disclosure
Reimbursement Expenses Related Entity
Related Party Transaction Release
Release Dates Remainder Page Intentionally Blank Signature Follows
Remainder Page Intentionally Left Blank Remainder Page Intentionally Omitted
Report Independent Registered Public Accounting Firm Reporting Violations Consequence
Reports Financial Statements Representations
Representations Warranties Parent Sub Representations Warranties Target
Research Development Research Development Costs
Research Development Grants Receivable Restraining Order
Restricted Cash Restricted Stock
Restricted Stock Award Restricted Stock Awards
Restricted Stock Units Restriction Period8221
Restructuring Cost Reduction Plan Results Operations
Results Operations 2005 2004 Results Operations 2007 2006
Results Operations 2008 2007 Results Operations Financial Condition
Retention Rights Revenue Recognition
Revenues Reverse Stock Split
Revision Right Payment
Rights Agreement Amendment Risk Factors
Risk-free Interest Rate Robert Johnston
Role Board Corporate Governance Matters Rubino
Rule 16b-3 Safe Harbor Statement
Safety Zoning Environmental Matters Satisfaction Conditions Precedent
Saves Money Schedule 14a
Schedules Securities Act
Securities Exchange Act 1934 Securities Law Requirements
Securities Laws Matters Security Ownership Certain Beneficial Owners Management Related Stockholder
See Accompanying Notes See Accompanying Notes Condensed Financial Statements
Select Consolidated Balance Sheet Data Selected Vela
Seq Severability
Severance Pay Share-based Payment
Shareholder Already Agreed Vote Favor Proposal Issue Merger Shareholders
Shareholders Expressed Intent Oppose Merger Shares
Shares Held Street Name Broker Vote Merger Proposals Sign-on Bonus
Signature Signature Page
Signature Page Follows Signatures
Sole Purpose Initiative Been Enhance Value Shareholders Solicitation
Soliciting Proxy Srinivas Akkaraju Phd
Stand-alone Additional Tandem Substitute Awards Standstill
Standstill Agreement Stock Appreciation Right
Stock Appreciation Rights Stock Listing
Stock Option Plans Stock Options
Stock Subject Plan Stock-based Compensation
Stockholder Signature Page Stockholders Meetings
Stockholders Proposals 2009 Annual Meeting Stockholdersrsquo Proposals 2008 Annual Meeting Stockholders
Strategy Strategy Operating Plan
Submission Jurisdiction Waivers Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Subsidiaries Subsidiary
Substitute Awards Successor Escrow Agent
Successors Assigns Survival Representations
Survivorship Tandem Stock Appreciation Rights
Target Disclosure Schedules Target Stockholders Meeting
Tax Consequences Parties Tax Fees
Tax Provision Tax Reporting Information Certification Identification Numbers
Tax Valuation Allowance Taxes
Taxes Tax Returns Technologies Subject License Termination Seriously Harm Business
Technologies Subject Licenses Termination Seriously Harm Business Term Awards
Term Employment Termination
Termination Corporation Cause Termination Corporation Change Control
Termination Corporation Other Change Control Death Disability Cause Termination Gamzu Good Reason Change Control
Termination Liabilities Consequent Thereon Termination Neill Good Reason
Termination Resulting Death Termination Rubino Good Reason Occurring After Anniversary Commencement
Termination Rubino Good Reason Occurring After Commencement Date Termination Rubino Good Reason Occurring Within Commencement Date
Terms Conditions Merger Terms Conditions Options
Terms Merger Changed Result 2006 Amendment Thomas Shrader
Tianeptine Treat Ibs Functional Dyspepsia Time Method Exercise
Title Property Leases Etc Total Assets
Total Current Assets Total Current Liabilities
Total Liabilities Total Operating Expenses
Total Shareholders Equity Transaction Overview
Transactions Transactions Affiliates
Transferability Transition Report Pursuant Securities Exchange Act 1934
Tricyclic Dextrocannabinoids Trust A-4 Lloyd Miller
Unfunded Status Awards Creation Trusts Unidentified Representative
Unregistered Sales Equity Securities Urge Read Proxy Materials Entirety They Become Available
Value Research Diminish Cannot Protect Enforce Intellectual Property Vela Acquisition Corporation Delaware
Vela Financing Analysis Vela Pharmaceuticals Inc
Vela Pharmaceuticals Inc Pro Forma Disclosure Velas Shareholders Able Sell Merger Shares They Receive
Venrock Associates Venrock Entrepreneurs Fund
Via Facsimile Vote Important
Voting Voting Agreement Waiver Among Lloyd Miller Trust A-4
Voting Escrow Shares Vpi-013 Treat Neuropathic Pain Hsdd
Waiver Breach Waivers
Warrants Weighted Average Exercise Price
Weighted Average Shares Outstanding What Being Asked Vote Respect Merger
What Happen Proposal Approve Issuance Merger Shares Approved What Happen Proposal Approve Issuance Merger Shares Not
What Happen Shares Common Stock Acquisition What Happens Return Proxy Not Indicate Vote Shares
What Need Now What Shareholder Approval Needed Connection Issuance Merger Shares
What Some Other Benefits Merger Shareholders Whereas
Withholding Taxes Witness Whereof
Witnesseth Wood Avenue South Suite 311 Iselin 08830 Address
Workplace Health Safety Laws Zelnorm Novartis
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki